Key considerations for advancing chimeric antigen receptor (CAR) T-cell therapy for systemic lupus erythematosus (SLE): a multi-partner/disciplinary working group perspective
Elena W.Y. Hsieh(Children's Hospital Colorado), Debra Zack(Fate Therapeutics (United States)), Aimee Payne(Columbia University Irving Medical Center), Ronald van Vollenhoven(Amsterdam University Medical Centers), James Chung(Amgen (United States)), Cindy Coney(Lupus Foundation of America), Patricia Rohan(National Institutes of Health), Jennifer C. Cooper(University of Colorado Anschutz Medical Campus), Beatrix Bartók(Gilead Sciences (United States)), Ashley K. Koegel(Bristol-Myers Squibb (United States)), Ann Eldred(AbbVie (United States)), Maria Dall’Era(University of California, San Francisco), Nikolay Delev(Bristol-Myers Squibb (Sweden)), Eric F. Morand(Novartis (Switzerland)), Paul Brunetta(Pharmaceutical Product Development (United States)), Meredith Jackson(Lupus Research Alliance), Jonathan J. Hogan(University of Pennsylvania), Vaishali Popat(Center for Biologics Evaluation and Research), Maximilian F. Konig(Johns Hopkins University), Gavin H. Imperato(Center for Biologics Evaluation and Research), Sandra Garcês(Amgen (United States)), Marlene J. Carrasco-Alfonso, Michel Sadelain(Columbia University Irving Medical Center), Shaun W. Jackson(Center for Infectious Disease Research), Georg Schett(Karolinska University Hospital), Naiyer A. Rizvi(Synthego (United States)), Richard Furie(Hofstra University), Gary A. Koretzky(Cornell University), Anca Askanase(Columbia University Irving Medical Center), Vijay Kumar(Center for Biologics Evaluation and Research), Aman P. Singh(Takeda (United States)), Monica Harrington(Fluent (United States)), Elaine Karis(Amgen (United States)), Katie Groover(Lupus Foundation of America), Artemio M. Jongco(GlaxoSmithKline (United States))
Cited by 3
Related Papers
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
|Science|2016|3.1k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Gene therapy comes of age
|Science|2018|1.4k